 visitante ::
identificación
|
|||||||||||||||
|
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español | |||||||||
| Página principal > Artículos > Artículos publicados > Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment |
(Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Hospital Universitari de Girona Doctor Josep Trueta) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Hospital de Sant Joan Despí Moisès Broggi) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Vall d'Hebron Institut d'Oncologia) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut d'Investigació Biomèdica de Bellvitge) (Institut Hospital del Mar d'Investigacions Mèdiques) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut Hospital del Mar d'Investigacions Mèdiques) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
| Fecha: | 2024 |
| Resumen: | Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment. |
| Ayudas: | Ministerio de Economía y Competitividad PT13/0010/0009 Ministerio de Economía y Competitividad PI16/01800 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-00723 Instituto de Salud Carlos III PI20/00625 Instituto de Salud Carlos III PI23/00591 Agència de Gestió d'Ajuts Universitaris i de Recerca 2023/SGR-00065 |
| Nota: | Altres ajuts: Generalitat de Catalunya (PERIS PFI-Salut SLT017-20-000076); Foundation for Cancer Research (grants 182496 and 215613); South-Eastern Norway Regional Health Authority (2018054) |
| Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.  |
| Lengua: | Anglès |
| Documento: | Article ; recerca ; Versió publicada |
| Materia: | Colorectal cancer ; Oxaliplatin ; Predictive biomarkers ; Luminex ; CXCL13 ; Tertiary Lymphoid Structures (TLS) |
| Publicado en: | Biomedicine & pharmacotherapy, Vol. 176 (July 2024) , ISSN 1950-6007 |
